Education
About Us
Working with TipRanks
Follow Us
Concord Biotech Ltd. (IN:CONCORDBIO)
:CONCORDBIO
Total Valuation
Concord Biotech Ltd. has a market cap or net worth of ₹152.42B. The enterprise value is ₹209.52B.
Market Cap₹152.42B
Enterprise Value₹209.52B
Share Statistics
Concord Biotech Ltd. has 104,616,200 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding104,616,200
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Concord Biotech Ltd.’s return on equity (ROE) is 0.21 and return on invested capital (ROIC) is 24.42%.
Return on Equity (ROE)0.21
Return on Assets (ROA)0.18
Return on Invested Capital (ROIC)24.42%
Return on Capital Employed (ROCE)0.33
Revenue Per Employee8.72M
Profits Per Employee2.70M
Employee Count1,377
Asset Turnover0.59
Inventory Turnover1.80
Valuation Ratios
The current PE Ratio of Concord Biotech Ltd. is 42.8. Concord Biotech Ltd.’s PEG ratio is 2.27.
PE Ratio42.8
PS Ratio14.50
PB Ratio9.60
Price to Fair Value9.60
Price to FCF127.69
Price to Operating Cash Flow0.00
PEG Ratio2.27
Income Statement
In the last 12 months, Concord Biotech Ltd. had revenue of 12.00B and earned 3.72B in profits. Earnings per share was 35.52.
Revenue12.00B
Gross Profit7.68B
Operating Income6.02B
Pretax Income4.95B
Net Income3.72B
EBITDA5.13B
Earnings Per Share (EPS)35.52
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
Concord Biotech Ltd. pays an annual dividend of ₹10.7, resulting in a dividend yield of 0.76%
Dividend Per Share₹10.7
Dividend Yield0.76%
Payout Ratio34.63%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.97
52-Week Price Change-31.60%
50-Day Moving Average1.53K
200-Day Moving Average1.68K
Relative Strength Index (RSI)36.33
Average Volume (3m)12.81K
Important Dates
Concord Biotech Ltd. upcoming earnings date is Feb 5, 2026, Before Open (Confirmed).
Last Earnings DateNov 13, 2025
Next Earnings DateFeb 5, 2026
Ex-Dividend DateSep 03, 2025
Financial Position
Concord Biotech Ltd. as a current ratio of 6.17, with Debt / Equity ratio of 0.09%
Current Ratio6.17
Quick Ratio4.87
Debt to Market Cap<0.01
Net Debt to EBITDA<0.01
Interest Coverage Ratio577.89
Taxes
In the past 12 months, Concord Biotech Ltd. has paid 1.23B in taxes.
Income Tax1.23B
Effective Tax Rate0.25
Enterprise Valuation
Concord Biotech Ltd. EV to EBITDA ratio is 33.93, with an EV/FCF ratio of 127.71.
EV to Sales14.50
EV to EBITDA33.93
EV to Free Cash Flow127.71
EV to Operating Cash Flow70.32
Balance Sheet
Concord Biotech Ltd. has ₹3.18B in cash and marketable securities with ₹0.00 in debt, giving a net cash position of ₹3.18B billion.
Cash & Marketable Securities₹3.18B
Total Debt₹0.00
Net Cash₹3.18B
Net Cash Per Share₹30.37
Tangible Book Value Per Share₹173.17
Margins
Gross margin is 66.74%, with operating margin of 50.16%, and net profit margin of 30.97%.
Gross Margin66.74%
Operating Margin50.16%
Pretax Margin41.21%
Net Profit Margin30.97%
EBITDA Margin42.72%
EBIT Margin38.34%
Analyst Forecast
The average price target for Concord Biotech Ltd. is ₹1,825.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target₹1,825.00
Price Target Upside29.35% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast3.63%
EPS Growth Forecast-1.21%